Effects of temozolomide and O6BG on DM6 melanoma xenografts
| Group | Quintupling time, mean ± SE (d) | Growth delay (d) | No. regressions | |||
|---|---|---|---|---|---|---|
| No modulation | ||||||
| ILI + 10% DMSO (control; n = 6) | 18.8 ± 2.2 | — | 1/6 | |||
| ILI + 350 mg/kg temozolomide (n = 6) | 17.3 ± 2.4 | −1.5 | 3/6 | |||
| ILI + 750 mg/kg temozolomide (n = 6) | 23.8 ± 4.3 | 5.1 | 3/6 | |||
| ILI + 750 mg/kg temozolomide (n = 6) with 40% PEG in PBS systemically × 5 d | 20.6 ± 3.1 | 3.3 | 2/6 | |||
| Modulation with 3.5 mg/kg O6BG × 1 d | ||||||
| ILI + 350 mg/kg temozolomide (n = 6) | 30.4 ± 4.8 | 11.7 | 3/6 | |||
| ILI + 750 mg/kg temozolomide (n = 6) | 42.5 ± 8.2* | 23.8 | 5/6† | |||
| Modulation with 3.5 mg/kg O6BG × 5 d‡ | ||||||
| ILI + 10% DMSO (control; n = 6) | 17.3 ± 2.5 | — | 0/6 | |||
| ILI + 350 mg/kg temozolomide (n = 6) | 39.8 ± 4.5§ | 22.6 | 5/6§ | |||
| ILI + 750 mg/kg temozolomide (n = 6) | 50.2 ± 5.5§ | 32.9 | 6/6§ | |||
| Systemic 35 mg/kg temozolomide (n = 6) | 13.7 ± 3.2 | −3.5 | 0/6 | |||
Abbreviation: ILI, isolated limb infusion.
↵* P < 0.01, versus ILI + 10% DMSO.
↵† P < 0.05, versus ILI + 10% DMSO.
↵‡ ILI with temozolomide or 10% DMSO was done 2 hours after first O6BG i.p. administration. O6BG was given every 24 hours for the next 4 days.
↵§ P < 0.01, versus ILI + 10% DMSO with 3.5 mg/kg O6BG for consecutive 5 days.